reports
InMed Pharmaceuticals Provides Update on its Core Research and Develop...
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces an update on its research/development and commercial activities. Eric A. Adams, InMed CEO, states, “The Company continues to execute on its research and development (“R&D”) plans to complete enrollment in a Phase 2 clinical program in e...
- Sean Conroy
InMed Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed Pharmaceuticals (INM), Onxeo (ONXEO), Arcane Crypto (ARCANE) and Aberdeen Diversified Income and Growth Trust (ADIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces, pursuant to a directors’ resolution, InMed will be consolidating all of its issued and outstanding share capital on the basis of one (1) post‐consolidation share for each twenty five (25) pre‐consolidation common shares of the Company (the “Consolidation”) in order to regain compl...
InMed Announces Changes to its Board of Directors
InMed Announces Changes to its Board of Directors VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing comple...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WNC WABASH NATIONAL CORPORATION
TSLA TESLA INC
STLD STEEL DYNAMICS INC.
SRPT SAREPTA THERAPEUTICS INC.
SEDG SOLAREDGE TECHNOLOGIES INC.
RGP RESOURCES CONNECTION INC.
PZZA PAPA JOHN'S INTERNATIONAL INC.
LTRX LANTRONIX INC.
I3N CHART INDUSTRIES INC.
FIX COMFORT SYSTEMS USA INC.
F FORD MOTOR COMPANY
DECK DECKERS OUTDOOR CORPORATION
CVX CHEVRON CORPORATION
CROX CROCS INC.
CLFD CLEARFIELD INC.
AXTI AXT INC.
ASTE ASTEC INDUSTRIES INC.
COWN COWEN INC CLASS A
SLCA U.S. SILICA HOLDINGS INC.
PTEN PATTERSON-UTI ENERGY INC.
WPC W. P. CAREY INC.
X UNITED STATES STEEL CORPORATION
TPIC TPI COMPOSITES INC.
XOM EXXON MOBIL CORPORATION
KRUS KURA SUSHI USA
VITL VITAL FARMS
IN. INMED PHARMACEUTICALS INC
SHLS SHOALS TECHNOLOGIES GROUP
RXDX PROMETHEUS BIOSCIENCES
OVV OVINTIV INC
SBTX SILVERBACK THERAPEUTICS
CVRX CVRX INC
STEM STEM INC
ENVX ENOVIX CORP
AVTE AEROVATE THERAPEUTICS INC
FLNC FLUENCE ENERGY INC
FWRG FIRST WATCH RESTAURANT GRP INC
HELA HELA APPAREL HOLDINGS LTD
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755...
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment International patent granted for the use of cannabinol for the treatment of epidermolysis bullosa VANCOUVER, British Columbia, July 25, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturin...
InMed Announces Appointment of Chief Operating Officer
InMed Announces Appointment of Chief Operating Officer VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, suppor...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum B...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance VANCOUVER, British Columbia, July 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a research, development, manufacturing corporation specializing in the commercialization of rare cannabinoids, announces that, as previously disclosed pursuant to a Form 8-K filed with the Securities Exchange Commission on June 21, 2022, the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market (“Nasdaq”) notifying ...
- Sean Conroy
InMed Pharmaceuticals - THCV launch expands rare cannabinoids portfoli...
InMed Pharmaceuticals has announced the launch of tetrahydrocannabivarin (d9-THCV) into B2B sales for the health and wellness industry. This marks the latest addition to its growing commercial footprint in high-value rare cannabinoids. Unlike tetrahydrocannabinol (THC), THCV is non-psychoactive and has shown indications of potential activity in combating obesity, diabetes, anxiety, Alzheimer’s disease and epilepsy. The launch and commercialization will be supported by InMed’s recently announced ...
InMed Announces Publication of Peer-Reviewed Study Highlighting Potent...
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences. The...
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for ...
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector Produces highly pure d9-dominant THCV, a non-intoxicating cannabinoidBolsters Company’s commercial portfolio, which also includes CBDV, CBC and CBTTHCV has been researched for a variety of potential benefits VANCOUVER, British Columbia, June 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the ...
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direc...
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules VANCOUVER, British Columbia, June 06, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single healthcare-focused institutional investor priced at-the-market under Nasdaq rules. The Compa...
InMed Pharmaceuticals Announces $5 Million Registered Direct and Priva...
InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules VANCOUVER, British Columbia, June 02, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4,079,256 of its common shares at a purchase price of $0.858 per share (or p...
- Sean Conroy
InMed Pharmaceuticals - Health and wellness product launches
InMed Pharmaceuticals has reported fiscal Q322 results (ending 31 March) benefiting from commercial sales into the health and wellness market. Its product launches of high-value rare cannabinoids contributed to its $0.3m revenues and should provide most sales in the near future. It has also made progress with its pharmaceutical drug development program for treating glaucoma, where it completed the FDA pre-investigational new drug (pIND) meeting for candidate INM-088. We continue to see InMed off...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Resu...
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel cannabinoid analogsAdvances the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization...
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy...
InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on cannabinoids for consumers, brands and healthcare providers VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and comme...
InMed Pharmaceuticals (INM): Notable launches of high-value rare canna...
Edison Investment Research Limited InMed Pharmaceuticals (INM): Notable launches of high-value rare cannabinoids 03-May-2022 / 12:00 GMT/BST London, UK, 3 May 2022 InMed Pharmaceuticals (INM): Notable launches of high-value rare cannabinoids InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future. INM also made notable advances in its pha...
- Sean Conroy
InMed Pharmaceuticals - Notable launches of high-value rare cannabinoi...
InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare cannabinoids into this market should provide the majority of its revenue in the near future. INM also made notable advances in its pharmaceutical drug development programs, including its ongoing 755-201-EB Phase II trial and preparing for an FDA pre-investigational new drug meeting on glaucoma ...
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Adva...
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the publication of a patent appl...
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabi...
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce it has launched B2B sales of the rare cannabinoid...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.